Ads
related to: ORPHAN MEDICAL INC
Search results
Editas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 5 days agoEditas Medicine, Inc. (NASDAQ:EDIT) Q1 2024 Earnings Call Transcript May 8, 2024 Editas Medicine, ...
Small Business - The Andalusia Star-News | The Andalusia Star-News
The Andalusia Star-News· 5 days agoSoligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases ...
Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare...
Digital Journal· 6 days agoJaguar's novel plant-based prescription drug crofelemer has been granted Orphan Drug Designation by the FDA and the European Medicines Agency for both MVID and SBS SAN FRANCISCO ...
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings Call Transcript Highlights: Soaring Sales and ...
GuruFocus.com via Yahoo Finance· 6 days agoA: (Joanne Quan, Chief Medical Officer) - The study design for volixibat in PSC assumes a conservative treatment difference of 1.75 points in pruritis...This is based on historical ...
Earnings call: Moleculin Biotech optimistic on Annamycin's future By Investing.com
Investing.com· 1 day agoMoleculin Biotech, Inc. (NASDAQ:MBRX), in its first quarter 2024 earnings call, highlighted...
Fulcrum Therapeutics Q1 2024 Earnings: Misses Analyst Net Income Projections Amid Strategic ...
GuruFocus.com via Yahoo Finance· 2 days agoFulcrum's ability to secure FDA Fast Track and Orphan Drug Designations for its lead compounds...
Poseida Therapeutics Provides Updates and Financial Results for the First Quarter of 2024
WRBL Columbus· 8 hours agoExpanded strategic relationship with Astellas with new research collaboration leveraging Poseida's proprietary allogeneic CAR-T platform to develop cell therapies targeting solid tumors Generated ...
Walgreens Launches Gene and Cell Services as Part of Newly
3BL CSRwire· 2 days agoWalgreens is expanding its specialty pharmacy services and investing in its capabilities as the...
Earnings call: Moleculin Biotech optimistic on Annamycin's future By Investing.com
Investing.com· 1 day agoMoleculin Biotech, Inc. (NASDAQ:MBRX), in its first quarter 2024 earnings call, highlighted...
BrainStorm Cell Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate...
WKRN Nashville· 8 hours agoBrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced financial results for ...
